Quantum Cyber N.V.QUCY
Price (close)
$1.33
Market cap
$111.8M
P/E
—
Revenue (FY)
$537,080
Net income
-$16.2M
Dividend yield
—
1-year total return
-14.2%
Net margin
-3018.3%
Revenue growth
-39.9%
Debt / equity
1.49x
What Quantum Cyber N.V. does.
tests for the early detection of cancer. In March 2025, we acquired a license from Liquid Bioscience, Inc. to access a portfolio of novel
mRNA biomarkers and AI developed proprietary algorithm, for the non-invasive detection of pancreatic cancer with a blood test. We have
an exclusive license to develop such a test using these biomarkers and algorithm with the unilateral option to acquire them. We are also
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $493,565 | $577,348 | $529,877 | $895,479 | $893,991 | $537,080 |
| Net income | -$586,895 | -$11.7M | -$26.4M | -$26.3M | -$21.6M | -$16.2M |
| Free cash flow | -$478,422 | -$3.2M | -$15.4M | -$23.1M | -$17.4M | -$11.0M |
More on QUCY.
- Quantum Cyber N.V. summary
- Quantum Cyber N.V. financial statements
- Quantum Cyber N.V. key metrics
- Quantum Cyber N.V. health scores and style box
- Quantum Cyber N.V. earnings
- Quantum Cyber N.V. dividends
- Quantum Cyber N.V. valuation
- Quantum Cyber N.V. ownership and insiders
- Quantum Cyber N.V. peers
Figures from Quantum Cyber N.V.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.